Table 2.
Gene Name | ACGT Chr Location | Region | % DM | Fold Change | Function |
---|---|---|---|---|---|
AI661453 | Chr17 47582589 | Genebody | 74%** | −2.02 | Cellular component |
Acaca | Chr11 84088161 | Genebody | 73%** | −2.01 | Long chain fatty acid biogenesis |
Abi1 | Chr2 22839713 | Genebody | 73%** | −2.03 | Negative regulation of cell growth and transformation, Ras signaling, Cardiovascular and placental development |
Aff2 | ChrX 66755393 | Genebody | 70%* | −2.02 | RNA‐binding protein |
Atf6 | Chr1 172773438 | Genebody | 79%* | −2.00 | Unfolded protein response during ER stress |
Arhgef12 | Chr9 42820787 | Genebody | 74%* | −2.02 | Acts as a guanine nucleotide exchange factor |
Ank | Chr15 27482616 | Genebody | 59%** | −2.03 | Osteoblast/osteoclast differentiation, hypoxia responsive/regulated by Hif1α |
Ank | Chr15 27513341 | Genebody | 78%** | −2.03 | |
Ank | Chr15 27427229 | Genebody | 21%* | −2.03 | |
Ank | Chr15 27430132 | Genebody | 52% | −2.03 | |
Atrnl1 | Chr19 58000444 | Genebody | 84%** | −4.06 | G‐protein coupled receptor signaling, may regulate energy homeostasis |
Atrnl1 | Chr19 57683177 | Promoter | 29% | −4.06 | |
Atrnl1 | Chr19 58054451 | Genebody | 35% | −4.06 | |
Atxn1 | Chr13 45770455 | Genebody | 67%** | −2.02 | Chromatin binding factor that represses Notch signaling. |
Brdt | Chr5 107807029 | Genebody | 75%** | −2.00 | Chromocenter organization, Spermatogenesis |
Cacna2d3 | Chr14 30485237 | Genebody | 74%** | −2.03 | Voltage‐gated calcium channel activity, Regulated by promoter methylation, contractility of ventricular myocytes |
Cacna2d3 | Chr14 30303225 | Genebody | 22% | −2.03 | |
Cd180 | Chr13 103491174 | Genebody | 66%* | −2.00 | Innate immune response, life/death decision of B‐cells |
Cdk14 | Chr5 4822015 | Genebody | 76%** | −4.07 | Cell cycle regulation |
Cdk14 | Chr5 5428041 | Enhancer | 23% | −4.07 | |
Casz1 | Chr4 148329448 | Enhancer | 80%** | −2.00 | Blood vessel development and lumen morphogenesis, differentially methylated in a tissue specific manner |
Cdh4 | Chr2 179440423 | Genebody | 75%** | −2.01 | Calcium dependent cell adhesion, may play a role in retinal development, Regulated by methylation |
Cdh4 | Chr2 179292446 | Genebody | 22% | −2.01 | |
Cdh4 | Chr2 179316146 | Genebody | 21% | −2.01 | |
Cdh4 | Chr2 179385054 | Genebody | 19%* | −2.01 | |
Clasp1 | Chr1 120296717 | Genebody | 75% | −2.03 | Regulation of microtubule dynamics, mitosis |
Chrna9 | Chr5 66367625 | Genebody | 71%** | −1.94 | Ion transport, cochlea hair development |
Chrna9 | Chr5 66348791 | Enhancer | 20%** | −1.94 | |
Col9a1 | Chr1 24203890 | Genebody | 63%** | −2.02 | Expressed in developing heart, differentially methylated in cancer |
Clasp2 | Chr9 113641090 | Enhancer | 69%** | −2.02 | Microtubule stabilization, mitosis |
Creb1 | Chr1 64569233 | Enhancer | 81%** | −2.02 | Gene transcription, HIF‐1‐alpha transcription factor network |
D6Wsu116e | Chr6 116164345 | Genebody | 76%** | −4.05 | N/A |
Csde1 | Chr3 102840451 | Genebody | 59%** | −2.00 | RNA binding and transcriptionally coupled mRNA turnover |
Disc1 | Chr8 127751886 | Genebody | 78%** | −2.02 | Multiple roles in embryonic and adult neurogenesis. Associated with schizophrenia |
Dach2 | ChrX 110423200 | Genebody | 65%** | −2.04 | Eye and limb development and sex determination |
Dgkb | Chr12 38744479 | Genebody | 73%** | −1.88 | Brain development |
Dnajc11 | Chr4 151311759 | Genebody | 78%** | −2.03 | Heat shock binding protein |
Dlx5 | Chr6 6859827 | Enhancer | 77%* | −2.03 | Transcriptional activator during bone development, Promotes cell proliferation, osteoblast differentiation. Cell type specific expression regulated by methylation |
Dnajc2 | Chr5 21291210 | Promoter | 69%** | 2.00 | DNA replication |
Dlg2 | Chr7 99358525 | Genebody | 60%** | −2.00 | Regulation of synaptic stability, Chronic pain perception |
Eif2ak4 | Chr2 118271831 | Genebody | 86%* | −2.01 | Hypoxia response |
Emilin2 | Chr17 71603514 | Genebody | 78%** | −4.05 | Extracellular matrix component, regulates methylation in breast cancer |
Emilin2 | Chr17 71606328 | Genebody | 74%** | −4.05 | |
Fam73a | Chr3 151956508 | Genebody | 81%** | −2.01 | Integral to membrane |
Fam111a | Chr19 12661528 | Genebody | 78%** | −2.02 | Simian virus 40 (SV40) host range restriction factor |
Fbxw7 | Chr3 84630582 | Genebody | 77** | −2.00 | Mediates ubiquitination and subsequent proteasomal degradation of target proteins including NOTCH1, inactivated by promoter hypermethylation |
Fancl | Chr11 26311200 | Genebody | 73%* | −2.04 | Mediates monoubiquitination, may play a role in primordial germ cell proliferation |
Fancl | Chr11 26368061 | Genebody | 96%* | −2.04 | |
Fbxw8 | Chr5 118558780 | Genebody | 92%* | −2.02 | Mediates ubiquitination and subsequent proteasomal degradation of target proteins, placental development |
Ftsjd2 | Chr17 29820177 | Genebody | 67%** | −2.01 | Methyltransferase that mediates mRNA cap1 |
Fscn1 | Chr5 143721993 | Promoter | 67%* | −2.03 | Cell migration, motility, adhesion and cellular interactions |
Has2 | Chr15 56549727 | Enhancer | 65%* | −16.31 | Heart valve development |
Grik4 | Chr9 42754379 | Promoter | 79%* | −2.04 | Glutamate receptor in CNS |
Invs | Chr4 48429137 | Genebody | 67%** | −4.05 | Embryonic heart tube left development and right pattern formation |
Invs | Chr4 48288832 | Promoter | 24%* | −4.05 | |
Il6st | Chr13 113256622 | Genebody | 77%* | −2.01 | Signal transduction. Plays a role in embryonic development, vascular endothelial growth |
Hipk2 | Chr6 38796532 | Genebody | 61%* | −2.00 | Angiogenesis, marked for degradation by hif1‐a in cancer |
Itgb1 | Chr8 131241575 | Genebody | 78%** | −2.03 | Promotes endothelial cell motility and angiogenesis, Hif1 regulated in wound healing |
Itsn1 | Chr16 91786820 | Genebody | 79%* | −2.02 | Adaptor protein linking endocytic membrane traffic and actin assembly machinery |
Isg20 | Chr7 86061520 | Genebody | 62%** | 3.97 | Viral response |
Itga1 | Chr13 115765151 | Genebody | 66%** | −2.04 | Integrin and Collagen Binding, rapid methylation leading to initiation of megakaryocyte differentiation |
Itga1 | Chr13 115800600 | Genebody | 20%** | −2.04 | |
Kcne4 | Chr1 78770239 | Enhancer | 77%** | 7.87 | Potassium voltage channel, cardiac function (cardiomyopathy) |
Kif26b | Chr1 180479937 | Genebody | 81%** | −2.00 | Embryonic kidney development, plays a role in compact adhesion between mesenchymal cells |
Klhl2 | Chr8 67366115 | Genebody | 76%* | −2.02 | Mediate ubiquitination of target proteins, Plays a role in the reorganization of actin cytoskeleton |
Ksr1 | Chr11 79001767 | Enhancer | 82%** | −2.04 | Promotes MEK and RAF phosphorylation and activity |
Ksr1 | Chr11 78904857 | Genebody | 20% | −2.04 | |
Limk1 | Chr5 135156130 | Genebody | 80%* | −2.04 | Regulation of actin filament dynamics, cell motility, cell cycle progression and differentiation |
Lmf1 | Chr17 25771254 | Genebody | 82%** | −2.04 | Maturation and transport of lipoprotein lipase through the secretory pathway |
Mkrn2 | Chr6 115567892 | Genebody | 62%* | 2.01 | Neurogenesis |
Ncoa7 | Chr10 30373619 | Genebody | 75%** | 2.02 | Co‐activation of several nuclear receptors |
Ncam1 | Chr9 49570879 | Genebody | 61%* | 4.06 | Neural adhesion, pathological angiogenesis in oxygen induced retinopathy, ventricular wall thickening in hypertension, cardiac protection |
Odz3 | Chr8 49397492 | Genebody | 73%** | −2.00 | Signal transduction, neuronal growth and tumorigenesis |
Odz3 | Chr8 49336206 | Genebody | 47%** | −2.00 | |
Odz3 | Chr8 49341811 | Genebody | 21% | −2.00 | |
Pam | Chr1 99716878 | Enhancer | 79%** | 4.07 | Heart development and hypoxia response |
Pde5a | Chr3 122538715 | Genebody | 79** | 2.02 | Signal transduction, cardiac muscle contraction and hypertrophy, hypoxia response |
Pde11a | Chr2 75840713 | Genebody | 70%* | 1.98 | Signal transduction, may play a role in vascular smooth muscle proliferation and contraction, cardiac contractility and immune cell activation |
Pcgf5 | Chr19 36450106 | Promoter | 71%* | 2.02 | Maintenance of transcriptional repressive state in development, including that of Hox genes |
Pfkfb3 | Chr2 11406131 | Genebody | 78%** | 2.03 | Induced by Hif1α |
Pet112 l | Chr3 85403998 | Genebody | 70%* | 2.03 | Glutamyl‐tRNA amidotransferase complex, Functions in mitochondria |
Pip5k1b | Chr19 24602322 | Genebody | 72%** | 4.06 | Phosphorylation |
Pnkd | Chr1 74336698 | Genebody | 65%** | 2.00 | Hydrolase activity, Plays an aggregative role in the development of cardiac hypertrophy via NF‐kappa‐B signaling |
Pou2f1 | Chr1 167866210 | Promoter | 70%** | −2.01 | Regulates gene expression in response to stress and metabolic signals |
Ppm1 h | Chr10 122245574 | Genebody | 67% | 4.05 | Phosphatase activity, drug response in cancer, associated with systemic lupus erythematosus |
Ppm1 h | Chr10 122144175 | Genebody | 19%** | 4.05 | |
Prdm16 | Chr4 153999781 | Genebody | 68%** | 2.02 | Transcriptional regulation, Functions as a repressor of TGF‐beta signaling |
Ppwd1 | Chr13 104995653 | Genebody | 67%** | 2.02 | Putative peptidylprolyl isomerase, may be involved in pre‐mRNA splicing |
Ptn | Chr6 36663240 | Enhancer | 75%** | 4.07 | Angiogenesis, tumorigenesis, regulation of hematopoietic stem cell self renewal, mammary gland development |
Prmt8 | Chr6 127665685 | Genebody | 79%* | −2.07 | Arginine methyltransferase, embryonic and neural development, regulated by auto‐methylation |
Prkca | Chr11 108120704 | Genebody | 86%** | 2.00 | Regulation of transcription, cell growth, immune response, negative regulation of cell proliferation, apoptosis, differentiation, cardiac hypertrophy and angiogenesis |
Ranbp3 | Chr17 56833581 | Genebody | 78%* | 2.02 | Nuclear export, negative regulator of TGF‐beta signaling through SMAD |
Ptpro | Chr6 137362114 | Genebody | 71%** | 2.00 | Wnt‐protein binding, Candidate tumor suppressor, aberrantly methylated in cancer |
Ptpru | Chr4 131336827 | Genebody | 69%** | 1.84 | Cell proliferation and migration, maintenance of epithelial integrity, neural development and possible megakaryocytopoiesis |
Rbfox3 | Chr11 118610022 | Genebody | 65%* | 1.97 | RNA‐binding, associated with neurocytoma and cerebral artery occlusion |
Rhd | Chr4 134418089 | Promoter | 81%** | −8.00 | Encodes member of Rh blood group proteins |
Rbm39 | Chr2 155977061 | Genebody | 75% | 4.05 | Transcriptional co‐activator for steroid nuclear receptors, involved in pre‐mRNA splicing |
Rpia | Chr6 70726365 | Genebody | 67%** | 2.02 | Carbohydrate metabolism |
Robo2 | Chr16 74182881 | Genebody | 72% | −2.00 | Heart Morphogenesis, linear hear tube formation, neuronal development |
Rpn2 | Chr2 157147564 | Genebody | 55%** | 2.04 | Ribosome binding, Dolichyl‐diphosphooligosaccharide‐protein glycotransferase activity |
Rsu1 | Chr2 13110936 | Genebody | 79%** | 2.01 | Ras signal transduction pathway |
Rsu1 | Chr2 13153759 | Genebody | 50%* | 2.01 | |
Rufy2 | Chr10 62447503 | Genebody | 65% | 2.03 | Alzheimer's disease |
Sav1 | Chr12 71078443 | Genebody | 76%** | 2.03 | Transcription, cell proliferation, cell death, cell migration, cell cycle exit, protein degradation and RNA splicing |
Slc24a2 | Chr4 86672633 | Genebody | 58%** | 2.03 | Calcium and potassium transport |
Slmap | Chr14 27308224 | Genebody | 79% | 4.07 | Myoblast fusion |
Slco5a1 | Chr1 12939917 | Genebody | 61% | −1.97 | Transporter activity |
Sorbs2 | Chr8 46655637 | Genebody | 79%** | 2.02 | Cytoskeletal adaptor activity and structural constituent of cytoskeleton |
Sorbs2 | Chr8 46649975 | Genebody | 20% | 2.02 | |
Stxbp6 | Chr12 46076554 | Genebody | 79%** | 1.96 | Regulates SNARE complex formation |
St8sia5 | Chr18 77402859 | Enhancer | 80%** | 2.02 | Synthesis of gangliosides |
Srsf9 | Chr5 115781199 | Genebody | 73% | 2.03 | Splicing |
Tex9 | Chr9 72307706 | Genebody | 67%** | 2.02 | — |
Tbc1d16 | Chr11 119004863 | Genebody | 64%** | 1.99 | Rab GTPase activator activity |
Tbc1d16 | Chr11 119017735 | Genebody | 76%** | 1.99 | |
Taf4a | Chr2 179700219 | Genebody | 72%** | 2.01 | Basal transcription |
Tet2 | Chr3 133187569 | Genebody | 85%** | 2.01 | DNA demethylation regulating transcription |
Tmem38a | Chr8 75105110 | Genebody | 69%** | 4.06 | Potassium channel activity |
Tnrc6a | Chr7 130306203 | Genebody | 73%** | 2.02 | Gene silencing by RNA and microRNA |
Tmem135 | Chr7 96306156 | Genebody | 82%* | 2.02 | Peroxisome organization |
Tmem135 | Chr7 96397839 | Genebody | 29% | 2.02 | |
Tubg2 | Chr11 101015396 | Promoter | 19% | −2.01 | Major constituent of microtubules, structural molecule activity |
Vmn1r73 | Chr7 12307910 | Enhancer | 63%** | 2.00 | — |
Wnk1 | Chr6 119946851 | Genebody | 86%** | −1.98 | Heart development, regulations of cell signaling, survival and proliferations, electrolyte homeostasis, cytoskeletal reorganization and sodium and chloride ion transport |
Zbtb20 | Chr16 43500263 | Genebody | 89%** | −2.01 | Transcription factor involved in hematopoiesis, oncogenesis and immune response |
Zbtb20 | Chr16 43219787 | Enhancer | 95% | −2.01 | |
Zbtb20 | Chr16 43343231 | Genebody | 98% | −2.01 | |
Zbtb20 | Chr16 43455368 | Genebody | 97% | −2.01 | |
Wnt6 | Chr1 74821915 | Genebody | 65% | −4.35 | Tissue development |
Zdhhc8 | Chr16 18231749 | Genebody | 72% | 4.00 | Susceptibility to schizophrenia |
Zfp385b | Chr2 77445243 | Genebody | 73%* | −2.02 | Metal ion, nucleic acid, p53, and zinc ion binding, Apoptotic processes |
Zfp385b | Chr2 77629407 | Genebody | 21%* | −2.02 | |
Enah | Chr1 183952945 | Promoter | 25% | −2.01 | |
Pkd2 | Chr5 104885245 | Promoter | 22% | 1.99 | Tubular morphogenesis, associated with autosomal dominant polycystic kidney disease |
Mylk2 | Chr2 152734667 | Promoter | 20% | −1.91 | Cardiac function and global muscle contraction |
Ppp1r1c | Chr2 79544612 | Promoter | 25% | −1.93 | Promotes cell cycle progression and increases cell susceptibility to TNF‐induced apoptosis |
Spns2 | Chr11 72304383 | Promoter | 59%** | −4.03 | Migration of myocardial precursors; cardiovascular, immunological and neural development |
Elf1 | Chr14 79879478 | Promoter | 31% | −4.05 | Endothelial transcription factor |
Ppp1r3c | Chr19 36813263 | Promoter | 44% | −2.01 | Glycogen synthase, Regulated by Hif1α |
Gucy1a3 | Chr3 81943306 | Genebody | 23%** | −2.02 | Cardiac function, vascular smooth muscle function |
Gucy1a3 | Chr3 81993497 | Enhancer | 23%** | −2.02 | |
Ank2 | Chr3 126729907 | Enhancer | 97% | −2.01 | Expression and targeting of SPTBN1 in neonatal cardiomyocytes and regulation of neonatal cardiomyocyte contraction rate |
Sfrp2 | Chr3 83534574 | Enhancer | 30% | 8.05 | Cell growth and differentiation, Wnt signaling, myogenesis and eye retinal development, methylation of gene is a potential marker for colorectal cancer |
Erbb4 | Chr1 68142043 | Genebody | 23% | −4.04 | Heart development, cardiac muscle differentiation and postnatal cardiomyocyte differentiation, CNS development, neural crest cell migration, gene transcription, cell proliferation, differentiation, migration and apoptosis |
Erbb4 | Chr1 68846422 | Genebody | 20% | −4.04 | |
Erbb4 | Chr1 68938673 | Genebody | 38% | −4.04 | |
Erbb4 | Chr1 68954441 | Genebody | 20% | −4.04 | |
Erbb4 | Chr1 69128731 | Genebody | 24% | −4.04 | |
Mysm1 | Chr4 94660067 | Enhancer | 28%** | −2.00 | Histone modification and transcriptional co‐activation |
Foxp1 | Chr6 98892345 | Genebody | 19% | −2.04 | Cardiomyocyte proliferation |
Foxp1 | Chr6 99008217 | Genebody | 22%* | −2.04 | |
Foxp1 | Chr6 99018432 | Genebody | 34% | −2.04 | |
Foxp1 | Chr6 99163145 | Genebody | 20% | −2.04 | |
Foxp1 | Chr6 99197140 | Genebody | 23% | −2.04 | |
Foxp1 | Chr6 99357158 | Genebody | 22% | −2.04 | |
Foxp1 | Chr6 99391693 | Enhancer | 43%* | −2.04 | |
Unc5c | Chr3 141321392 | Genebody | 19% | −8.07 | Cell migration in neural development, axon extension and induction of apoptosis |
Unc5c | Chr3 141342275 | Genebody | 26% | −8.07 | |
Unc5c | Chr3 141359065 | Genebody | 20% | −8.07 | |
Sox5 | Chr6 143990289 | Genebody | 20% | −4.01 | Embryonic development, cell fate determination, transcriptional regulation |
Sox5 | Chr6 144141969 | Genebody | 19% | −4.01 | |
Psd3 | Chr8 70278799 | Genebody | 19%* | −2.03 | Guanine nucleotide exchange factor for ARF6 |
Psd3 | Chr8 70338543 | Genebody | 96% | −2.03 | |
Psd3 | Chr8 70459139 | Genebody | 23%* | −2.03 | |
Dock1 | Chr7 142059905 | Genebody | 28% | −2.01 | Cytoskeletal rearrangements necessary for phagocytosis of apoptotic cells and in cell motility Guanine nucleotide exchange factor |
Dock1 | Chr7 142061686 | Genebody | 19% | −2.01 | |
Dock1 | Chr7 142073658 | Genebody | 30% | −2.01 | |
Dock1 | Chr7 142115224 | Genebody | 24% | −2.01 | |
Dock1 | Chr7 142136783 | Genebody | 24% | −2.01 | |
Dock1 | Chr7 142190260 | Genebody | 53% | −2.01 | |
Wwox | Chr8 117142250 | Genebody | 31% | −2.03 | Apoptosis, TGFB1 signaling and TGFB1‐mediated cell death. Inhibits Wnt signaling |
Wwox | Chr8 117354691 | Genebody | 26% | −2.03 | |
Wwox | Chr8 117632214 | Genebody | 22% | −2.03 | |
Vegfc | Chr8 55148115 | Enhancer | 21% | 2.02 | Angiogenesis and endothelial cell growth |
Vegfc | Chr8 55239360 | Genebody | 18.5%* | 2.02 | |
Vegfc | Chr8 55247617 | Genebody | 22% | 2.02 | |
Pard3 | Chr8 129591554 | Genebody | 28%* | −2.00 | Adaptor protein, asymmetrical cell division and cell polarization, plays a role in epithelial tight junctions |
Pard3 | Chr8 129640346 | Genebody | 96%** | −2.00 | |
Pard3 | Chr8 129830952 | Genebody | 96% | −2.00 | |
Pard3 | Chr8 129845627 | Genebody | 21%** | −2.00 | |
Pard3 | Chr8 129875488 | Genebody | 22% | −2.00 | |
Pard3 | Chr8 129914177 | Genebody | 24% | −2.00 | |
Thsd4 | Chr9 59846658 | Genebody | 19%* | −2.00 | Attenuates TGFB signaling |
Thsd4 | Chr9 59968525 | Genebody | 22% | −2.00 | |
Thsd4 | Chr9 60041974 | Genebody | 19%* | −2.00 | |
Thsd4 | Chr9 60098887 | Genebody | 96%* | −2.00 | |
Rora | Chr9 68624882 | Genebody | 19%** | −2.01 | Regulated genes involved in lipid metabolism |
Rora | Chr9 68726640 | Genebody | 24%** | −2.01 | |
Rora | Chr9 68865723 | Genebody | 19% | −2.01 | |
Utrn | Chr10 12126998 | Genebody | 20%* | 2.02 | Anchors cytoskeleton to plasma membrane |
Utrn | Chr10 12213501 | Genebody | 20% | 2.02 | |
Utrn | Chr1012395503 | Genebody | 19% | 2.02 | |
Mef2c | Chr13 83687636 | Genebody | 96% | −1.99 | Transcription activator controls cardiac morphogenesis and myogenesis, plays a role in vascular development |
Mef2c | Chr13 83755977 | Genebody | 30%** | −1.99 | |
Mef2c | Chr13 83797333 | Genebody | 25% | −1.99 | |
Odz2 | Chr11 35940645 | Genebody | 35%* | −1.98 | Neural development |
Odz2 | Chr11 36164904 | Genebody | 20%* | −1.98 | |
Odz2 | Chr11 36400641 | Genebody | 32%** | −1.98 | |
Odz2 | Chr11 36725324 | Genebody | 27%** | −1.98 | |
Ptprk | Chr10 27825617 | Genebody | 20%* | −2.01 | Regulation of cell contact and adhesions, tumor invasion/metastasis, Negative regulator of EGFR signaling |
Ptprk | Chr10 28084547 | Genebody | 24% | −2.01 | |
Ptprk | Chr10 28226602 | Genebody | 24%** | −2.01 | |
Enox1 | Chr14 77538059 | Enhancer | 97% | −2.00 | Oxidoreductase activity, nucleotide binding |
Enox1 | Chr14 77771534 | Genebody | 23% | −2.00 | |
Enox1 | Chr14 77876556 | Genebody | 20%* | −2.00 | |
Enox1 | Chr14 77977395 | Genebody | 20%** | −2.00 | |
Zfpm2 | Chr15 40787554 | Genebody | 29% | −2.01 | Transcription regulator important in heart morphogenesis and coronary vessel development from epicardium |
Zfpm2 | Chr15 40824705 | Genebody | 95%** | −2.01 | |
Zfpm2 | Chr15 40848971 | Genebody | 19% | −2.01 | |
Dach1 | Chr14 98263585 | Genebody | 97%* | −1.99 | Transcription factor important in organogenesis |
Dach1 | Chr14 98304412 | Genebody | 26% | −1.99 | |
Dach1 | Chr14 98510700 | Genebody | 96% | −1.99 | |
Erc2 | Chr14 28475844 | Genebody | 97% | −1.99 | Cytomatrix organization at nerve terminal active zones regulating release of neurotransmitters |
Erc2 | Chr14 28668685 | Genebody | 30% | −1.99 | |
Erc2 | Chr14 28822634 | Genebody | 95% | −1.99 | |
Erc2 | Chr14 28845440 | Genebody | 24% | −1.99 | |
Vps13b | Chr15 35600466 | Genebody | 23%** | −1.99 | Protein sorting in post Golgi membrane traffic, may play a role in development and function of the eye, hematological system and the CNS |
Vps13b | Chr15 35777972 | Genebody | 19% | −1.99 | |
Vps13b | Chr15 35817931 | Genebody | 23%* | −1.99 | |
2810403A07Rik | Chr3 88506464 | Genebody | 84% | −2.01 | RNA binding |
Tle4 | Chr19 14528880 | Genebody | 20%* | −2.01 | Transcriptional co‐repressor of members in Wnt signaling |
Tle4 | Chr19 14621827 | Genebody | 24% | −2.01 | |
Prkg1 | Chr19 30823222 | Genebody | 19%* | −2.02 | Regulates cardiac function, smooth muscle contraction, platelet activation and adhesion |
Prkg1 | Chr19 31528132 | Genebody | 24% | −2.02 | |
Prkg1 | Chr19 31595749 | Genebody | 20% | −2.02 | |
Hif1a | Chr12 75032797 | Genebody | 25% | −2.00 | Hypoxia response, Master transcriptional regulator |
Malt1 | Chr18 65586771 | Promoter | 19%* | −2.00 | NF‐kappaB activation |
Igf2r | Chr17 12965268 | Promoter | 44% | −2.02 | Activation of TGF‐β. Intracellular trafficking of lysosomal enzymes and degradation of IGF2, tumorigenesis, Paternally imprinted |
Krtap9‐1 | Chr11 99731190 | Promoter | 27% | 8.00 | Hair shaft formation |
Ccdc40 | Chr11 119085948 | Promoter | 20% | −4.03 | Motile cilia function. Ciliary dyskinesia type 15 |
Cftr | Chr6 18119186 | Promoter | 20% | −2.00 | Chloride channel and enzyme binding, associated with cystic fibrosis |
Cftr | Chr6 18242079 | Genebody | 42% | −2.00 | |
Pdzd2 | Chr15 12315935 | Genebody | 23% | 2.02 | Prostate tumorigenesis |
Pdzd2 | Chr15 12342544 | Genebody | 27% | 2.02 | |
Pdzd2 | Chr15 12521967 | Promoter | 19% | 2.02 | |
Elovl2 | Chr13 41317598 | Promoter | 23% | −4.04 | Atherosclerosis, protein binding and fatty acid elongase activity |
Gpr18 | Chr14 122316980 | Promoter | 96% | 1.98 | Regulation of immune system, bipolar disorder |
Rpn1 | Chr6 88030514 | Promoter | 24% | −2.01 | Dolichyl‐diphosphooligosaccharide‐protein glycotransferase activity |
Mosc1 | Chr1 186637543 | Promoter | 19% | −4.12 | — |
Tmem150c | Chr5 100589921 | Promoter | 25% | −2.04 | — |
Shroom3 | Chr5 93236380 | Promoter | 27% | −2.01 | Regulation of cell shape in neuroepithelium |
Calb1 | Chr4 15806105 | Promoter | 24% | −1.95 | Functions in purkinje cells |
Gpr61 | Chr3 107962781 | Promoter | 22%** | 8.01 | G‐protein coupled receptor signaling |
Cd40 | Chr2 164871483 | Enhancer | 96% | −2.02 | Immune and inflammatory response |
Ephx1 | Chr1 182951005 | Promoter | 23% | 2.02 | Cis‐stilbene‐oxide hydrolase activity, epoxide hydrolase activity. Plays a role in preeclampsia |
Arhgap29 | Chr3 121628392 | Enhancer | 96% | −2.00 | Rho GTPase activator activity, essential role in blood vessel tubulogenesis |
Fbxl4 | Chr4 22244260 | Enhancer | 21% | −2.02 | Cell cycle control |
Fbxl4 | Chr4 22264607 | Enhancer | 21% | −2.02 | |
Zmat3 | Chr3 32233835 | Genebody | 96%** | −1.96 | TP53‐dependent growth regulatory pathway and TP53‐mediate apoptosis, inhibits tumor cell growth |
Zmat3 | Chr3 32278426 | Enhancer | 22% | −1.96 | |
Fam125b | Chr2 33790838 | Enhancer | 23%** | −2.03 | Vesicular trafficking |
Serpinb2 | Chr1 109370955 | Enhancer | 31% | −4.08 | Serine‐type endopeptidase inhibitor activity |
Rims1 | Chr1 22615396 | Genebody | 97%* | −2.02 | Exocytosis, maintenance of neurotransmitter release and regulation of release during short‐term synaptic plasticity |
Rims1 | Chr1 22763512 | Genebody | 96% | −2.02 | |
Dst | Chr1 34249899 | Genebody | 20% | −2.01 | Cytoskeletal linker protein, Regulation of keratinocyte polarity and mobility |
Dst | Chr1 34315083 | Genebody | 20% | −2.01 | |
Dst | Chr1 34322642 | Genebody | 26% | −2.01 | |
Etl4 | Chr2 20373784 | Genebody | 23% | 2.00 | Intervertebral disk development |
Etl4 | Chr2 20576360 | Genebody | 95%* | 2.00 | |
Esrrg | Chr1 189527991 | Genebody | 46% | −2.00 | Transcriptional activator via estrogen response elements |
Esrrg | Chr1 189976300 | Genebody | 21%* | −2.00 | |
Dnm3 | Chr1 163949959 | Genebody | 22% | −1.99 | Megakaryocyte development, likely involved in endocytosis |
Dnm3 | Chr1 164108264 | Genebody | 40%** | −1.99 | |
Rbms1 | Chr2 60615270 | Genebody | 25% | −2.02 | Cell cycle progression, apoptosis, DNA replication and gene transcription. |
Rbms1 | Chr2 60789032 | Genebody | 19% | −2.02 | |
Lrba | Chr3 86163560 | Genebody | 23% | −2.01 | Signal transduction and vesicle trafficking |
Lrba | Chr3 86267521 | Genebody | 21% | −2.01 | |
Plcb1 | Chr2 134819839 | Genebody | 23% | −1.99 | Intracellular transduction of extracellular signals |
Plcb1 | Chr2 135145732 | Genebody | 25% | −1.99 | |
Meis2 | Chr2 115688950 | Genebody | 96% | −2.01 | Transcriptional regulation |
Meis2 | Chr2 115750462 | Genebody | 96% | −2.01 | |
Bach2 | Chr4 32560314 | Genebody | 21%* | −2.00 | Transcriptional regulation |
Bach2 | Chr4 32629036 | Genebody | 21% | −2.00 | |
Kcnd3 | Chr3 105447527 | Genebody | 16%* | −1.84 | Smooth muscle contraction, heart rate, insulin secretion, neuronal excitability and cell volume |
Fam19a1 | Chr6 96068370 | Genebody | 31% | −1.91 | Regulators of immune cells and cells of the nervous system |
Fam19a1 | Chr6 96235296 | Genebody | 19%** | −1.91 | |
Drosha | Chr15 12715566 | Enhancer | 22% | −2.03 | Cleaves ds‐RNA in micro RNA processing |
Drosha | Chr15 12817558 | Genebody | 27% | −2.03 | |
Gsk3b | Chr16 38062422 | Enhancer | 20% | −2.01 | Negative regulator in hormonal control of glucose homeostasis, Wnt signaling and the regulation of transcription factors and microtubules. Regulates NFatc1 expression. Mediates development of insulin resistance |
Gsk3b | Chr16 38138300 | Genebody | 20%** | −2.01 | |
Gsk3b | Chr16 38218276 | Genebody | 96% | −2.01 | |
Pmm2 | Chr16 8627532 | Enhancer | 33% | −2.02 | Glycoprotein biosynthesis |
Osta | Chr16 32515415 | Enhancer | 31% | −2.00 | Transporter activity |
Krt8 | Chr15 101867475 | Enhancer | 23% | −4.02 | Signal transduction and cellular differentiation |
Slc38a4 | Chr15 96905406 | Enhancer | 96% | −2.00 | Sodium‐dependent amino acid transporter |
Slc38a2 | Chr15 96516885 | Enhancer | 20%* | −2.03 | Supply of maternal nutrients to fetus through placenta, transport of amino acids at blood‐brain barrier |
Adra2a | Chr19 54118496 | Promoter | 26% | 1.99 | Mediates the catecholamine‐induced inhibition of adenylate cyclase |
Table provides differentially expressed genes with corresponding differential methylation (DM) sites. Bolded DM values indicate decreased methylation at E14.5 whilst unbolded DM values indicates increased methylation at E14.5.
*Notes P<0.05 in methylation changes and **notes P<0.01 in methylation changes. Gene functions are summarized.